Isf LLC

Gruppo Lepetit

Inverni Della Beffa Spa

Craf Sud

I D B Holding S.p.a.

Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.

Inverni Della Beefa S.p.a.

Giorgio Pifferi

Mario Pinza

Carlo Farina

Pietro Consonni

Riccardo Monguzzi

Giampietro Broccali

Marisa Conti

Salvatore Malandrino

Amedeo Omodei-Sale'

Luciano Dorigotti

Raffaello Giorgi

Alberto Diena

Ezio Bombardelli

Bruno Gabetta

Giovanni Gaviraghi

Claudio Semeraro

Renato Pellegata

Amedeo Omodei-Sale

Roberto P Giani

Maria J Magistretti

Piero Valenti

Silvano Banfi

Paolo Colombo

Amedeo Omodei Sale

Goffredo Bolis

Antonio C Cardona

Gaetano Clavenna

Paolo Da Re

Carlo Carpi

Bonaccorso Rosselli Del Turco

Afro Gamba

Achille Umani-Ronchi

Rita Nizzola

Bonaccorso R Del Turco

Cetylpyridinium salt of an anti-inflammatory agent and pharmaceutical compositions containing it

This invention concerns systems for the release of active principles which are capable of releasing active principle(s) into an aqueous medium at a controlled rate. More precisely, the invention concerns a monolithic system for the controlled release of active principles, consisting of:

Multilayer matrix systems for the controlled release of active principles

The novel compounds 3,6-Disubstituted xanthen-9-one of formula I ##STR1## in which R is a C.sub.3 -C.sub.8 linear, branched or cyclic alkyl and R.sub.1 is linear, branched C.sub.1 -C.sub.8 alkyl or cyclic C.sub.3 -C.sub.8 alkyl or --OR in which R is as defined hereinabove, exhibit bone resorption inhibiting activity. Pharmaceutical compositions are described.

Xanthone derivatives, their preparation and use

The anthocyanidins pelargonidin and delphidin, have been found to possess novel and unexpected activity in the ophthalmic field, specifically that they are active in reducing the permeability of ciliary body vessels. According to one aspect of the present invention there is provided a method of reducing the hyperpermeability of the ciliary body ocular vessels in a subject which comprises administering to the subject an effective dose of pelargonidin or delphidin. The invention further provides the use of pelargonidin or delphidin in the manufacture of pharmaceutical compositions for carrying out the method of treatment referred to above.

Methods and pharmaceutical compositions for the treatment of ophthalmic

A class of benzothiazepine esters having structures related to that of diltiazem are provided which possess vasodilating activity while being virtually free of cardiodepressive effects. The esters are useful in the treatment of arterial hypertension and disturbances of the cerebral circulation. The compounds have the general formula I ##STR1## wherein R represents hydrogen or an electronegative group (preferably a halogen atom, or a nitro, trifluoromethyl or methoxy group); and

Benzothiazepine esters, their preparation and formulations for

Novel water-soluble derivatives of silybin of enhanced activity are provided as well as methods of preparing the derivatives and pharmaceutical compositions containing them. The novel derivatives according to the invention have the following general formula (I); ##STR1## where: R=H or PO(OH).sub.2 and R'=PO(OH).sub.2 The compounds of the invention are useful inter alia in therapy of liver disorders and other applications where an anti-radical effect is required. They have the advantages of high hydrophilicity and are soluble at approximately pH 4, compared to prior art compounds which are water-soluble only at higher pH and enhanced stability.

Soluble derivatives of silybin, a method of preparing them, and

Benzoyoxyacetic acid derivatives of formula (I) ##STR1## wherein M denotes hydrogen or one equivalent of a pharmaceutically acceptable inorganic or organic cation are useful as analgesics and anti-inflammatory agents. A novel process for their preparation is also disclosed along with novel intermediates.

Derivatives of benzoyloxyacetic acid, and preparation and formulations

The invention relates to novel compounds comprising lipophilic complexes of silybin, silidianin, and silicristin with phospholipids, and the preparation of these complexes by non-conventional methods. Absorption of the novel compounds in the gastrointestinal tract is appreciably greater, resulting in higher plasma levels than for the individual flavanolignans. The resulting improvement in the pharmacokinetic and pharmacological parameters is such that the substances can advantageously be used in the treatment of acute and chronic liver disease of toxic, metabolic or infective origin or of degenerative nature.

Complexes of flavanolignans with phospholipids, preparation thereof and

Preparation of ethyl {6-[ethyl-(2-hydroxypropyl)amino]-3-pyridazinyl}hydrazino carboxylate is disclosed, from 3-chloro-6-hydrazinopyridazine in protected form, which is oxidized to yield the corresponding azo derivative, which is treated with ethyl-(2-hydroxypropyl)amine in the presence of strong bases, the corresponding amino derivative being subjected to reduction and deprotection, and finally acylated to yield ethyl{6-[ethyl-(2-hydroxypropyl)amino]-3-pyridazinyl}hydrazinocarboxylate.

Triphenylmethyl azo and hydrazino substituted pyridazines

Preparation of ethyl {6-[ethyl-(2-hydroxypropyl)amino]-3-pyridazinyl} hydrazino carboxylate is disclosed from 3-chloro-6-hydrazinopyridazine in protected form, which is oxidized to yield the corresponding azo derivative, which is treated with ethyl-(2-hydroxypropyl)amine in the presence of strong bases, the corresponding amino derivative being subjected to reduction and deprotection, and finally acylated to yield ethyl {6-[ethyl-(2-hydroxypropyl)amino]-3-pyridazinyl} hydrazinocarboxylate.

Process of making

There are described a new pharmaceutically active derivative of ursolic acid, 3.beta.-(3-carboxypropionyloxy)ursa-9(11),12-dien-28-oic acid, which possesses activity as an anti-ulcer and anti-viral agent, pharmaceutically acceptable, non-toxic salts thereof, a method of preparing the same and compositions containing the same.

Pharmaceutically active ursolic acid derivative

Formyl derivatives of hydrazinopenicillins of the formula ##STR1## wherein R is thienyl or phenyl, R' is hydrogen, formyl or alkyl containing from 1 to 3 carbon atoms and R' is hydrogen or formyl, provided that at least one of R' and R' is a formyl group, the carbon atom with the asterisk indicating a center of asymmetry of the molecule, and pharmaceutically acceptable salts and esters thereof, as mixture or as separated epimers. These compounds have antibacterial activity against Gram-negative and Gram-positive bacteria and are prepared by a process wherein the corresponding hydrazinopenicillin is reacted under anhydrous conditions with acetoformic anhydride to give the desired compounds.

Formyl derivatives of hydrazinopenicillins

There are described new alkoxyalkylidenhydrazinopyridazines having antihypertensive activity having the formula: ##STR1## wherein R is alkyl or cycloalkyl having up to 5 carbon atoms, optionally substituted with unsubstituted phenyl, substituted phenyl or cycloalkyl, R.sub.1 is hydrogen or alkyl having 1 to 3 carbon atoms and R.sub.2 is alkyl having 1 to 3 carbon atoms, a carboxylic group or phenyl and the process for their preparation.

Alkoxyalkylidenhydrazinopridazines and process for their preparation

Hydrazono penicillin derivatives of the formula ##STR1## wherein R represents phenyl optionally substituted, 2- or 3- thienyl optionally substituted, or 2- or 3-furyl optionally substituted, R.sub.1 represents hydrogen, alkyl containing from 1 to 4 carbon atoms, or phenyl, and R.sub.2 represents hydrogen, pivaloyloxymethyl, or 1-(ethoxycarbonyloxy)ethyl radical. The compounds have antibacterial activity against gram-negative and gram-positive microorganisms. Methods of preparation are also disclosed.

Hydrazono penicillin derivatives

Hydrazono derivatives of cephalosporins of the formula ##STR1## wherein R is phenyl optionally substituted, 2- or 3-thienyl optionally substituted, or 2- or 3-furyl optionally substituted, R.sub.1 is hydrogen or alkyl having from 1 to 4 carbon atoms, and R.sub.2 is hydrogen, acetoxy, carbamoyloxy or a heterocyclic nucleus preferably bounded through a sulphur atom to the methylene group. The compounds have bactericidal activity. Methods of preparation are also disclosed.

Hydrazono derivatives of cephalosporins

Growing community of inventors

Milan, Italy

Giorgio Pifferi